That’s a great question. We have a lot more to do in terms of understanding the patient-reported quality of life. I mean, in terms of just the reported toxicities, we did see more fatigue as expected. We saw more, especially grade one, grade two, neurological side effects. We saw some more hypertension. But reassuringly, there was no difference in cardiac and no difference in seizures for enzalutamide, which I know people have been worried about...
That’s a great question. We have a lot more to do in terms of understanding the patient-reported quality of life. I mean, in terms of just the reported toxicities, we did see more fatigue as expected. We saw more, especially grade one, grade two, neurological side effects. We saw some more hypertension. But reassuringly, there was no difference in cardiac and no difference in seizures for enzalutamide, which I know people have been worried about. So, you know, I think overall the quality of life differences were probably as one would expect with enzalutamide, but we’re going to delve into that more deeply.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
